FindTrial
Sign In

RBX2660

DRUG4 trials

Sponsors

Rebiotix Inc., Ferring Pharmaceuticals

Conditions

Clostridium Difficile InfectionClostridium Difficile Infection (CDI)Clostridium Difficile Infection RecurrenceCommunicable DiseasesInfection

Phase 2

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
CompletedNCT02589847
Rebiotix Inc.Clostridium Difficile Infection
Start: 2015-10-31End: 2019-03-31Updated: 2021-03-26

Phase 3

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)
CompletedNCT03244644
Rebiotix Inc.Clostridium Difficile Infection (CDI)
Start: 2017-07-31End: 2020-08-03Updated: 2024-07-10
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)
CompletedNCT03931941
Rebiotix Inc.Clostridium Difficile Infection, Communicable Diseases, Infection
Start: 2019-07-30End: 2023-07-21Updated: 2024-08-07
A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection
CompletedNCT05831189
Ferring PharmaceuticalsClostridium Difficile Infection Recurrence
Start: 2023-04-21End: 2025-01-17Updated: 2026-04-24

Related Papers

Efficacy Outcomes of Fecal Microbiota, Live-jslm in Preventing Recurrent Clostridioides difficile Infection from Seven Clinical Studies.
2026-06-12
Safety and Efficacy of Fecal Microbiota, Live-jslm for Prevention of Recurrent Clostridioides difficile Infection Among Hospitalized Participants in PUNCH CD3-OLS
Infectious Diseases and Therapy2026-02-07
Integrated analysis of the safety of fecal microbiota, live-jslm in adults with recurrent <i>Clostridioides difficile</i> infection from five prospective clinical trials: an update.
2025-11-12
Prevention of recurrent <i>Clostridioides difficile</i> infection by fecal microbiota, live-jslm (REBYOTA<sup>®</sup>) administered via colonoscopy: 6-month data from the single-arm phase IIIb CDI-SCOPE trial.
2025-11-09
Patient-reported benefits of colonoscopicallyadministered microbiota restoration therapy: a qualitative study of adult patients with recurrent <i>Clostridioides difficile</i> infection
Therapeutic Advances in Gastroenterology2025-11-01
Microbiome and metabolome changes after fecal microbiota, live-jslm, administration are associated with health-related quality of life improvements.
2025-10-18
Safety and Efficacy of Fecal Microbiota, Live-jslm to Prevent Recurrent Clostridioides difficile Infection in Participants With Irritable Bowel Syndrome.
2025-08-10
Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS.
2025-08-015 citations
Decreased Antimicrobial Resistance Gene Richness Following Fecal Microbiota, Live-jslm (REBYOTA®) Administration: Post Hoc Analysis of PUNCH CD3
Open Forum Infectious Diseases2025-07-02
Microbiome and Metabolome Restoration After Administration of Fecal Microbiota, Live-jslm (REBYOTA) for Preventing Recurrent Clostridioides difficile Infection.
2025-07-017 citations
Microbiome compositional changes and clonal engraftment in a phase 3 trial of fecal microbiota, live-jslm for recurrent <i>Clostridioides difficile</i> infection
Gut Microbes2025-06-244 citations
Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA <sup>®</sup> ) administered by colonoscopy for prevention of recurrent <i>Clostridioides difficile</i> infection: 8-week results from CDI-SCOPE, a single-arm, phase IIIb trial
Therapeutic Advances in Gastroenterology2025-04-224 citations
Safety and Efficacy of Fecal Microbiota, Live-jslm, in Preventing Recurrent <i>Clostridioides difficile</i> Infection in Participants Who Were Mildly to Moderately Immunocompromised in the Phase 3 PUNCH CD3-OLS Study
Open Forum Infectious Diseases2025-03-043 citations
A71 SUBGROUP ANALYSIS OF CANADIAN PARTICIPANTS IN PUNCH CD3-OLS: A PHASE 3 OPEN-LABEL CLINICALSTUDY TO EVALUATE THE SAFETY AND EFFICACY OF FECAL MICROBIOTA, LIVE-JSLM, IN ADULTS WITH RECURRENT <i>CLOSTRIDIOIDES DIFFICILE</i> INFECTION
Journal of the Canadian Association of Gastroenterology2025-02-01
Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection : Subgroup Analysis of PUNCH CD2 and PUNCH CD3.
2024-09-016 citations
PUNCH CD3-OLS: A Phase 3 Prospective Observational Cohort Study to Evaluate the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA) in Adults With Recurrent <i>Clostridioides difficile</i> Infection
Clinical Infectious Diseases2024-08-2323 citations
Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), Among Patients Exposed to Non–<i>Clostridioides difficile</i> Infection Antibiotics: Post Hoc Subgroup Analysis of a Phase 2 Open-Label Study
Open Forum Infectious Diseases2024-06-143 citations
Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection.
2024-01-185 citations
Prescription Microbiome Therapeutic for Recurrent Clostridioides difficile Infection: Fecal Microbiota Live-jslm
The American Journal of Gastroenterology2023-12-281 citations
706. An Ad Hoc Subgroup Analysis of a Phase 3, Open-Label Study Indicates Efficacy and Safety of Fecal Microbiota, Live-jslm in Participants With Recurrent <i>Clostridioides difficile</i> Infection and Renal Impairment
Open Forum Infectious Diseases2023-11-27

16 more papers not shown